Supplementary Materials for: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial
Published: 10 September 2025| Version 1 | DOI: 10.17632/b3h7kzthc5.1
Contributors:
Jianzhong Zhang, Cheng Zhou, Guoying Miao, Shoumin Zhang, Xinsuo Duan, Liming Wu, Guoqiang Zhang, Ningning Dang, Yangfeng Ding, Hongfang Han, Aihua Wei, Bin Yang, Linfeng Li, Shanshan Li, Xunyi Dai, Jianglin Zhang, Tiechi Lei, Wenjie Yan, Lixia Zhang, Zudong Meng, Rixin Chen, Qiuhe Song, Liangchun Wang, Wenhui Wang, Xinglin Hu, Ziyong Xiang, Zhe Shi, Ling ZhangDescription
This dataset contains supplementary materials for the following publication: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial published in the Journal of the American Academy of Dermatology. Supplementary materials include supplementary methods, 3 supplementary figures, and 4 supplementary tables.
Files
Categories
Tyrosine Kinase Inhibitor, Psoriasis, Clinical Trial Results